课题基金 / 基金详情

项目摘要

项目成果

Barney Graham的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Respiratory syncytial virus (RSV) infection is the primary cause of respiratory infection in young children, causing >120,000 hospitalizations in the US annually. RSV vaccine development has been hampered by the history of a failed vaccine trial in the early 1960s in which vaccinated children were not protected against subsequent natural infection but rather experienced more severe disease. Subsequent experiments in animal models and human subjects suggest the occurrence of severe RSV disease correlates with the induction of virus-specific Th2 CD4+ T cells and eosinophil recruitment and degranulation. The putative attachment G glycoprotein of RSV and killed virus vaccines containing adjuvants such as alum are particularly effective in inducing such disease-enhancing immune responses. The purposes of these studies are 1) to define the precise components of RSV immunity that predispose for severe RSV disease upon subsequent exposure to the virus, 2) to determine how the structure of RSV contributes to disease, and 3) with this better understanding of RSV pathogenesis, to rationally design RSV vaccines that protect against infection without enhancing disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cellular Immune Responses to RSV infection in Mice
Rapid Development of Vaccines for Emerging Viruses
Vectors and Methods to Increase Immunogenicity during DNA Vaccination
HIV Preventive Vaccine Studies
海外基金